Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

25%(1 trials)

Phase Distribution

Ph phase_2

20%

Ph phase_1

40%

Ph phase_3

20%

Ph phase_4

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

2(40.0%)

Phase 2Efficacy & side effects

1(20.0%)

Phase 3Large-scale testing

1(20.0%)

Phase 4Post-market surveillance

1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Other(1)

Detailed Status

Completed4

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (40.0%)

Phase 21 (20.0%)

Phase 31 (20.0%)

Phase 41 (20.0%)

Trials by Status

unknown120%

completed480%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_3

A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients

NCT05815901

completedphase_1

Febuxostat Effect on Chronic Kidney Disease Progression And Carotid Intima-Media Thickness

NCT06997952

unknownphase_4

Clinical Trials (5)

Showing 5 of 5 trials

NCT05815901Phase 3

A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients

Completed

NCT06997952Phase 1

Febuxostat Effect on Chronic Kidney Disease Progression And Carotid Intima-Media Thickness

Completed

NCT03534037Phase 4

Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction

Unknown

NCT02246673Phase 2

RDEA3170 and Febuxostat Combination Study in Gout Subjects

Completed

NCT01883167Phase 1

RDEA3170 and Febuxostat Drug Interaction Study

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5